Stryker
STRYKER CORP
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$25.1B
Operating marginCalculated
19.5%
Net assets to total assetsCalculated
Could not be retrieved
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
19.5%
Growth (revenue, 4-year average)
★★★★☆position among all companies
10.1%
Capital efficiency
Could not be retrieved
Revenue and profit
Performance, financial position and capital allocation
Stryker
Recent performance trends
Stryker
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$17.1 billion | US$18.4 billion | US$20.5 billion | US$22.6 billion | US$25.1 billion |
| Operating income | US$2.6 billion | US$2.8 billion | US$3.9 billion | US$3.7 billion | US$4.9 billion |
| Net income | US$2.0 billion | US$2.4 billion | US$3.2 billion | US$3.0 billion | US$3.2 billion |
| Total assets | US$34.6 billion | US$36.9 billion | US$39.9 billion | US$43.0 billion | US$47.8 billion |
| Net cash provided by (used in) operating activities | US$3.3 billion | US$2.6 billion | US$3.7 billion | US$4.2 billion | US$5.0 billion |
| Net cash provided by (used in) investing activities | US$-0.9 billion | US$-2.9 billion | US$-1.0 billion | US$-3.0 billion | US$-4.9 billion |
| Net cash provided by (used in) financing activities | US$-2.4 billion | US$-0.7 billion | US$-1.6 billion | US$-0.5 billion | US$0.1 billion |
| Cash and cash equivalents | US$2.9 billion | US$1.8 billion | US$3.0 billion | US$3.7 billion | US$4.0 billion |
Revenue scale in the same industry
Stryker
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- 4 MedlineFY Dec 2025 US$28.4B
- 5 StrykerThis companyFY Dec 2025 US$25.1B
- 6 3MFY Dec 2025 US$24.9B
- 7 DanaherFY Dec 2025 US$24.6B
- … 36 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.8 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$4.0 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$0.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-4.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$5.0 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$1.6 billion | Consolidated | Disclosed |
| Dividends paid | US$1.3 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$22.4 billion | Consolidated | Disclosed |
| Net sales | US$25.1 billion | Consolidated | Disclosed |
| Operating income | US$4.9 billion | Consolidated | Disclosed |
| Net income | US$3.2 billion | Consolidated | Disclosed |
| Total assets | US$47.8 billion | Consolidated | Disclosed |
| Operating margin | 19.5% | Consolidated | Calculated |
| Net assets to total assets | Cannot be calculated | Not applicable | Not calculated (no stockholders' equity in this year's 10-K) |
| Net margin | 12.9% | Consolidated | Calculated |
| Return on equity | Cannot be calculated | Not applicable | Not calculated (no stockholders' equity in this year's 10-K) |